WO1994022451B1 - Selective regulation of b lymphocyte precursors by hormones - Google Patents
Selective regulation of b lymphocyte precursors by hormonesInfo
- Publication number
- WO1994022451B1 WO1994022451B1 PCT/US1994/003844 US9403844W WO9422451B1 WO 1994022451 B1 WO1994022451 B1 WO 1994022451B1 US 9403844 W US9403844 W US 9403844W WO 9422451 B1 WO9422451 B1 WO 9422451B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hormone
- production
- hormones
- cells
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Abstract
It has been determined that estrogen and other hormones elevated in pregnancy induce a specific modulation of lymphocyte precursor cell production. The immune system of an animal or bone marrow cells in culture can therefore be modulated in a specific manner by administration of hormones elevated during pregnancy, such as estrogen and estrogen-like compounds or compounds that interfere with the synthesis or activity of these hormones, to increase or decrease production of B lymphocyte precursor cells.
Claims
AMENDED CLAIMS
[received by the International Bureau on 30 September 1994 (30.09.94); original claims 1-20 replaced by amended claims 1-12 (3 pages)]
i 1. A method for modulating production of mammalian B lymphocyte precursor cells comprising exposing the cells to a hormone selected from the group consisting of hormones elevated during pregnancy, synthetic analogues of the hormones elevated during pregnancy, eliciting agents of the hormones elevated during pregnancy, and antagonists of the hormones elevated during pregnancy, in an amount effective to alter selectively the production of mammalian B lymphocyte precursor cells.
2. The method of claim 1 wherein the hormone is selected from the group of natural and synthetic hormones consisting of estrogen, estrone, estradiol, estriol, progesterone, and combinations thereof and the amount is effective to inhibit selectively the production of mammalian B lymphocyte precursor cells.
3. The method of claim 1 wherein the hormone is selected from the group consisting of chorionic gonadotropin, hormone eliciting agents, hormone antagonists, and combinations thereof and the amount is effective to manipulate selectively the production of mammalian B lymphocyte precursor cells.
4. The method of claim 1 wherein the hormone is administered to cells in culture.
5. The method of claim 1 wherein the hormone is administered to a patient in need of treatment to alter selectively the production of mammalian B lymphocyte precursor cells. β. The method of claim 5 wherein the patient has an autoimmune disorder and the amount is effective to decrease selectively the production of mammalian B lymphocyte precursor cells and thereby decrease selectively the production of mature B lymphocytes which secrete autoantibodies.
7. The method of claim 5 further comprising administering to a patient in need of treatment to increase calcium deposition by stromal cells of bone marrow a hormone selected from the group consisting of chorionic gonadotropin, hormone eliciting agents, hormone antagonists, and combinations thereof in an amount effective to increase calcium deposition by stromal cells of bone marrow.
8. The method of claim 4 wherein the cells are bone marrow cells in culture.
9. The method of claim 3, wherein the hormone is administered to a patient in need of treatment.
10. The method of claim 9, wherein the patient has an autoimmune disorder and the amount is effective to decrease production of B lymphocyte precursor cells by proliferation or differentiation and thereby decrease production of mature B lymphocytes that secrete autoantibodies.
11. The method of claim 9, wherein the patient has an immune deficiency disease and the amount is effective to increase production of B lymphocyte precursor cells by proliferation or differentiation and thereby increase production of mature B lymphocytes.
12. The method of claim 9, further comprising administering to a patient in need of treatment a hormone selected from the group consisting of
chorionic gonadotropin, hormone eliciting agents, agents that interfere with the synthesis or activity of the hormones elevated during pregnancy,
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4428093A | 1993-04-07 | 1993-04-07 | |
| US044,280 | 1993-04-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1994022451A1 WO1994022451A1 (en) | 1994-10-13 |
| WO1994022451B1 true WO1994022451B1 (en) | 1994-11-10 |
Family
ID=21931485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1994/003844 Ceased WO1994022451A1 (en) | 1993-04-07 | 1994-04-07 | Selective regulation of b lymphocyte precursors by hormones |
Country Status (2)
| Country | Link |
|---|---|
| US (2) | US5494899A (en) |
| WO (1) | WO1994022451A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5696128A (en) * | 1994-07-07 | 1997-12-09 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Method of regulating immune function |
| US5859001A (en) | 1996-01-11 | 1999-01-12 | University Of Florida Research Foundation, Inc. | Neuroprotective effects of polycyclic phenolic compounds |
| US6319504B1 (en) | 1996-06-24 | 2001-11-20 | University Of Maryland Biotechnology Institute | Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin |
| US5968513A (en) * | 1996-06-24 | 1999-10-19 | University Of Maryland Biotechnology Institute | Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin |
| US6583109B1 (en) | 1997-06-24 | 2003-06-24 | Robert C. Gallo | Therapeutic polypeptides from β-hCG and derivatives |
| US20030083231A1 (en) * | 1998-11-24 | 2003-05-01 | Ahlem Clarence N. | Blood cell deficiency treatment method |
| US6667299B1 (en) | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
| US7994278B1 (en) | 1999-08-06 | 2011-08-09 | Nobel Biosciences Llc | Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA) |
| DE50016101D1 (en) * | 1999-08-13 | 2011-06-09 | Curadis Gmbh | SUBSTANCES AND MEANS FOR THE POSITIVE INFLUENCE OF COLLAGEN |
| CA2345478A1 (en) * | 2000-11-29 | 2002-05-29 | University Of Guelph | Uterine natural killer cells |
| US7658926B2 (en) * | 2001-09-14 | 2010-02-09 | Opexa Pharmaceuticals, Inc. | Autologous T-cell vaccines materials and methods |
| AU2002358540A1 (en) * | 2001-11-30 | 2003-06-10 | Solvay Pharmaceuticals Gmbh | Treatment of th2 dominated immunological disease states with progesterone receptor antagonists |
| RU2327487C2 (en) * | 2002-08-08 | 2008-06-27 | Бейлор Колледж Оф Медисин | Release and identification of t-cells |
| EP1641916B1 (en) | 2003-06-27 | 2016-02-17 | DePuy Synthes Products, Inc. | Regeneration and repair of neural tissue using postpartum-derived cells |
| US9220813B2 (en) * | 2005-04-18 | 2015-12-29 | Holy Cross Hospital, Inc. | Cell therapy for limiting overzealous inflammatory reactions in tissue healing |
| EP2016414B1 (en) * | 2006-05-05 | 2015-09-02 | Opexa Therapeutics | T-cell vaccine |
| US9453204B2 (en) * | 2008-07-14 | 2016-09-27 | Oklahoma Medical Research Foundation | Production of pluripotent cells through inhibition of bright/ARID3a function |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4078060A (en) * | 1976-05-10 | 1978-03-07 | Richardson-Merrell Inc. | Method of inducing an estrogenic response |
| US4383993A (en) * | 1980-05-30 | 1983-05-17 | University Of Kentucky Research Foundation | Nasal dosage forms containing natural female sex hormones |
| US4701450A (en) * | 1984-03-21 | 1987-10-20 | Akzo N.V. | Steroids for use as immunomodulators |
| US4729999A (en) * | 1984-10-12 | 1988-03-08 | Bcm Technologies | Antiestrogen therapy for symptoms of estrogen deficiency |
| NL8403381A (en) * | 1984-11-07 | 1986-02-03 | Akzo Nv | Use of 4-oestrene-17-ol steroid(s) as immuno:modulators - esp. for treating auto:immune diseases |
| US4762717A (en) * | 1986-03-21 | 1988-08-09 | The General Hospital Corporation | Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive |
| JPH0621072B2 (en) * | 1986-11-12 | 1994-03-23 | 呉羽化学工業株式会社 | Immunomodulator consisting of estradiol derivative |
| US4900734A (en) * | 1987-08-27 | 1990-02-13 | Maxson Wayne S | Novel pharmaceutical composition containing estradiol and progesterone for oral administration |
-
1994
- 1994-04-07 WO PCT/US1994/003844 patent/WO1994022451A1/en not_active Ceased
- 1994-04-07 US US08/224,236 patent/US5494899A/en not_active Expired - Lifetime
- 1994-10-11 US US08/321,156 patent/US5554595A/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1994022451B1 (en) | Selective regulation of b lymphocyte precursors by hormones | |
| Djiane et al. | Prolactin–progesterone antagonism in self regulation of prolactin receptors in the mammary gland | |
| US4288546A (en) | Process for the large scale production of pituitary hormones by serial secondary suspension culture | |
| Uckun | Regulation of human B-cell ontogeny | |
| Bennett et al. | Characterization of insulin-like growth factor I receptors on cultured rat bone cells: regulation of receptor concentration by glucocorticoids | |
| Goldspink et al. | Protein turnover measured in vivo and in vitro in muscles undergoing compensatory growth and subsequent denervation atrophy | |
| Tucker | Hormones, mammary growth, and lactation: a 41-year perspective | |
| Van Horn | The relation of the thyroid to the hypophysis and ovary | |
| Carson et al. | Growth factors in ovarian function | |
| Mueller et al. | Effects of warm and cold temperatures on release of TSH, GH, and prolactin in rats | |
| PT82978A (en) | Process for producing dry bioactive recombinant growth hormones | |
| Beyer et al. | Sexual behavior in pregnant and lactating domestic rabbits | |
| Hornsby | Regulation of adrenocortical cell proliferation in culture | |
| US5554595A (en) | Selective regulation of B lymphocyte precursors by hormones | |
| Voogt et al. | Suppression of proestrous and suckling-induced increase in serum prolactin by hypothalamic implant of prolactin | |
| TERASAWA et al. | Positive feedback effect of progesterone on luteinizing hormone (LH) release in cyclic female rhesus monkeys: LH response occurs in two phases | |
| Messer et al. | Changes in response to calcitonin following prolonged administration to intact rats | |
| EP0219447B1 (en) | Antigestagens for postponing endometrial maturation | |
| Goswami et al. | Gonadotrophin-induced oocyte maturation in the catfish, Heteropneustes fossilis (Bloch), requires steroidogenesis in both interrenal and ovary | |
| Neumann et al. | Influence of sexual hormones on the differentiation of neural centers | |
| Lau et al. | Picomolar norethindrone in vitro stimulates the cell proliferation and activity of a human osteosarcoma cell line and increases bone collagen synthesis without an effect on bone resorption | |
| Hammond et al. | Somatomedin (Sm) production by cultured porcine granulosa cells (GC) | |
| Machado et al. | Efficacy of norethindrone acetate and norgestomet implants in suppressing estrus in female beef cattle | |
| Lopez et al. | Secretion kinetics of prolactin and growth hormone by mouse anterior pituitaries in long term organ cultures | |
| Smith et al. | Inhibitory action of oestrogen on calcium-induced mitosis in rat bone marrow and thymus |